{"product_id":"bcrx-swot-analysis","title":"(BCRX) BioCryst Pharmaceuticals, Inc. SWOT Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Research Trail Behind the Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis BioCryst Pharmaceuticals, Inc. SWOT Analysis gives a concise, company-specific view of its strengths, weaknesses, opportunities, and threats—useful for research, strategy, or investment decisions. The page already includes a genuine preview\/sample of the analysis so you can judge format and depth before buying; purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStrengths\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 marketed products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc. has 2 marketed products: Peramivir injection and ORLADEYO, which gives it real commercial sales instead of relying only on pipeline bets. ORLADEYO remains the core value driver; BioCryst reported full-year 2024 net ORLADEYO revenue of about $405 million, showing strong market traction. That live product base also gives management real-world launch and payer data, which helps investor confidence versus a pure-development biotech.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral small-molecule focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc. focuses on oral, small-molecule medicines, a setup that fits chronic and rare diseases where long-term use matters. Its lead drug, ORLADEYO, is a once-daily oral therapy for hereditary angioedema, and oral dosing can support better convenience and adherence than injectables.\u003c\/p\u003e\n\u003cp\u003eThis platform also lowers treatment burden for patients and caregivers, which can matter in rare-disease care where frequent visits are a drag.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eORLADEYO in hereditary angioedema\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eORLADEYO is a once-daily oral prophylactic for hereditary angioedema, a rare disease affecting about 1 in 50,000 people, so BioCryst Pharmaceuticals can charge premium pricing and keep recurring use. In 2024, ORLADEYO remained BioCryst's main revenue driver, which shows how a focused rare-disease franchise can anchor growth. \u003c\/p\u003e\n\u003cp\u003eIts oral dosing also helps it compete against infused HAE therapies, a key edge in a market with long-term treatment needs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-asset pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc. has a multi-asset pipeline with three active clinical programs: BCX9930 in Phase II, plus BCX9250 and galidesivir in Phase I. That gives the Company multiple shots on goal across different disease areas, so one setback does not sink the whole story.\u003c\/p\u003e\n\u003cp\u003eA broader pipeline can also spread clinical and regulatory risk better than a single-asset model. In biotech, that matters because most programs fail before approval, so having more than one late-stage path improves the odds of a future value driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 active clinical programs\u003c\/li\u003e\n\u003cli\u003ePhase II and Phase I spread\u003c\/li\u003e\n\u003cli\u003eLess reliance on one asset\u003c\/li\u003e\n\u003cli\u003eMore potential catalysts ahead\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal and institutional partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc. has a strong edge in global and institutional partnerships through Torii Pharmaceutical, Seqirus, Shionogi, BARDA, and NIAID. These ties can bring non-dilutive funding, shared trial costs, and deeper scientific know-how, which helps BioCryst Pharmaceuticals, Inc. move programs faster and spread risk across more partners.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePharma, government, and academic reach\u003c\/li\u003e\n\u003cli\u003eFunding support without heavy dilution\u003c\/li\u003e\n\u003cli\u003eAccess to expertise and trial leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioCryst’s Rare-Disease Revenue Engine Is Already Working\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc. stands out for having a real commercial base: ORLADEYO drove about $405 million in 2024 net revenue, while Peramivir adds a second marketed product. Its once-daily oral rare-disease model supports adherence and premium pricing. A 3-program pipeline and major partners like Torii, Seqirus, and BARDA also spread risk and funding.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eORLADEYO revenue\u003c\/td\u003e\n\u003ctd\u003e$405 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketed products\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive clinical programs\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear SWOT framework for analyzing BioCryst Pharmaceuticals, Inc.’s business strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eHelps quickly identify BioCryst Pharmaceuticals’ SWOT pain points for faster strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary industry reports, SEC filings, clinical trial registries, and peer‑reviewed studies to speed due diligence and verify key assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eWeaknesses\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue tied to few products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc. still relies on just two marketed products, so one weak launch can hit results fast. ORLADEYO drives most sales, while RAPIVAB is seasonal and much smaller, which keeps revenue concentrated. That mix can make earnings swing sharply if competition rises, demand slows, or one product loses momentum.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEarly-stage pipeline risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc. still carries high early-stage pipeline risk: BCX9250 and galidesivir remain in Phase I, while BCX9930 is only in Phase II. Early clinical programs often fail before approval, and the long time to readouts can delay any clear revenue outlook. That leaves future cash flow tied to programs with limited human data and no late-stage validation yet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-franchise exposure in HAE\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eORLADEYO drove nearly all of BioCryst Pharmaceuticals, Inc.'s about $439 million in 2024 revenue, so the business still leans on one HAE franchise. That concentration means if HAE growth slows, there are few near-term offsetting drivers to cushion results. It also weakens resilience if pricing, competition, or reimbursement pressure hits ORLADEYO.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLimited scale versus large pharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioCryst is a Durham-based biotech with a narrow product and pipeline base, so its commercial and manufacturing reach is still much smaller than large pharma peers with $10B+ annual revenue and global supply chains. That smaller scale can weaken pricing power, market access, and bargaining strength with suppliers, distributors, and payers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocused portfolio, not broad scale\u003c\/li\u003e\n\u003cli\u003eLess leverage in pricing talks\u003c\/li\u003e\n\u003cli\u003eWeaker global reach and supply depth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePeramivir is an acute-use product\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePeramivir is an acute-use IV antiviral for uncomplicated influenza, so BioCryst Pharmaceuticals, Inc. gets demand tied to flu-season spikes rather than steady daily use. It is a single 600 mg dose, which makes it useful in acute care but limits repeat purchasing. That keeps it a smaller, less stable growth driver than chronic therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSeasonal demand only\u003c\/li\u003e\n\u003cli\u003eSingle-dose use limits repeat sales\u003c\/li\u003e\n\u003cli\u003eSmaller revenue base than chronic drugs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioCryst’s Heavy ORLADEYO Dependence Clouds Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc. is still exposed to heavy concentration risk: ORLADEYO drove nearly all of about $439 million 2024 revenue, so one franchise still sets the tone. Its pipeline is also early, with BCX9250 and galidesivir in Phase I and BCX9930 in Phase II, which leaves little late-stage proof. That mix limits visibility and keeps cash flow tied to a narrow base.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue concentration\u003c\/td\u003e\n\u003ctd\u003eAbout $439 million 2024 revenue; ORLADEYO dominant\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline risk\u003c\/td\u003e\n\u003ctd\u003eBCX9250, galidesivir Phase I; BCX9930 Phase II\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScale gap\u003c\/td\u003e\n\u003ctd\u003eNarrower reach than large pharma peers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eBioCryst Pharmaceuticals, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is pulled directly from the full report on BioCryst Pharmaceuticals, Inc., summarizing strengths, weaknesses, opportunities, and threats with actionable insights. Purchase unlocks the complete, editable version for immediate download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eOpportunities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCX9930 Phase II expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBCX9930, BioCryst Pharmaceuticals, Inc.'s oral factor D inhibitor, is in Phase II for complement-mediated diseases and could move into rare and immune-mediated indications if data stay strong. That would give BioCryst Pharmaceuticals, Inc. a second growth engine beyond hereditary angioedema, where Orladeyo remains the core franchise. Success in Phase II would also widen the addressable market and reduce product concentration risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCX9250 in FOP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBCX9250, an oral ALK-2 inhibitor in Phase I for fibrodysplasia ossificans progressiva, targets an ultra-rare disease affecting about 1 in 1 million people worldwide. With no approved cure and very limited options, even small efficacy gains could support orphan pricing and a differentiated asset for BioCryst Pharmaceuticals, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGalidesivir antiviral optionality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGalidesivir gives BioCryst Pharmaceuticals, Inc. optionality because it has shown activity against RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. That broad scope could open multiple development paths, from outbreak response to biodefense contracts. It also fits government preparedness funding, where antiviral stockpiles and fast-track programs can support non-dilutive capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership-led development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioCryst already works with companies and public bodies, so partnership-led development can cut its R and D load and speed the next programs. With just one marketed drug, ORLADEYO, the company can use licensing, co-development, and grant support to spread risk and tap outside expertise faster.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLess internal R and D spend\u003c\/li\u003e\n\u003cli\u003eFaster access to niche know-how\u003c\/li\u003e\n\u003cli\u003eLower trial and launch risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat matters as BioCryst scales beyond ORLADEYO and keeps capital focused on the highest-return assets. Partnering can also bring non-dilutive funding, which helps protect cash while expanding the pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeographic and label expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePeramivir’s multi-brand footprint—RAPIVAB, RAPIACTA, and PERAMIFLU—gives BioCryst Pharmaceuticals, Inc. a clear path to expand outside the U.S. and into new channels. The drug’s single-dose IV profile can help win hospital and pandemic-use contracts, while label expansion can extend life beyond seasonal flu demand. In 2024, RAPIVAB remained the main U.S. brand for influenza treatment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMultiple brands support regional licensing\u003c\/li\u003e\n\u003cli\u003eHospital use can widen access\u003c\/li\u003e\n\u003cli\u003eNew labels can extend the product life cycle\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioCryst’s Pipeline Expands Growth Options Beyond ORLADEYO\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOpportunities center on expanding BCX9930 and BCX9250 into rare-disease niches, while galidesivir and peramivir add optionality beyond ORLADEYO. BioCryst Pharmaceuticals, Inc. can also use partnerships to share R and D risk and bring in non-dilutive funding, which matters as it pushes more shots at long-term growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBCX9930\u003c\/td\u003e\n\u003ctd\u003ePhase II expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBCX9250\u003c\/td\u003e\n\u003ctd\u003eUltra-rare FOP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGalidesivir\u003c\/td\u003e\n\u003ctd\u003eOutbreak and biodefense\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeramivir\u003c\/td\u003e\n\u003ctd\u003eGlobal label growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eThreats\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial failure risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc. still has several pipeline assets in Phase I and Phase II, so safety or efficacy misses could wipe out a big part of expected future value. Biotech failure rates stay high in early testing, and one weak readout can cut funding, delay approvals, or force a reset. That risk matters because BioCryst Pharmaceuticals, Inc. depends on pipeline success to deepen growth beyond ORLADEYO.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition in rare disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eORLADEYO faces a crowded hereditary angioedema market, where U.S. patients already have 5 preventive options, so any rival with better efficacy, safety, or dosing can win share. BioCryst’s 2024 net ORLADEYO sales were $536.7 million, so even a small shift in uptake can move revenue fast. Stronger competition can also cap pricing power and squeeze future margin expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory uncertainty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc.'s pipeline still hinges on FDA and ex-U.S. regulator calls, and any delay, complete response letter, or extra study request can push commercialization back. That risk is sharper for unapproved assets, where approval odds and timelines are less certain. Even with ORLADEYO as the only marketed drug, pipeline slippage can hurt future revenue growth and R\u0026amp;D returns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReimbursement and pricing pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc. depends on payer coverage for specialty and rare-disease drugs like ORLADEYO, so reimbursement cuts can hit access fast. In a market where a small patient pool can still drive most sales, even modest net-price erosion can slow revenue growth after approval.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePayers can narrow coverage or raise prior auth.\u003c\/li\u003e\n\u003cli\u003eGovernment cost controls can cut net pricing.\u003c\/li\u003e\n\u003cli\u003eApproval does not guarantee full revenue capture.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDependence on partners and funding sources\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc. leans on in-license and collaboration deals, so its pipeline depends on outside partners as much as internal execution. If a partner cuts funding or shifts priorities in 2025, development timelines can slip and trial work can slow. That creates concentrated execution risk because one strained relationship can affect multiple programs at once.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner priorities can change fast.\u003c\/li\u003e\n\u003cli\u003eFunding cuts can delay development.\u003c\/li\u003e\n\u003cli\u003eExternal reliance raises execution risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioCryst’s Pipeline Risks and ORLADEYO Rivalry Could Pressure Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioCryst Pharmaceuticals, Inc. still faces heavy pipeline risk: early-stage failures can erase value fast, and any Phase I\/II miss can slow funding and push back approvals. ORLADEYO also faces a crowded hereditary angioedema market with 5 U.S. preventive options, so better rivals can take share from its $536.7 million 2024 net sales base.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline risk\u003c\/td\u003e\n\u003ctd\u003ePhase I\/II assets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eORLADEYO competition\u003c\/td\u003e\n\u003ctd\u003e5 U.S. preventive options\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue exposure\u003c\/td\u003e\n\u003ctd\u003e$536.7M 2024 net sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234094784777,"sku":"bcrx-swot-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/bcrx-swot-analysis.webp?v=1785712700","url":"https:\/\/dcfanalyst.com\/products\/bcrx-swot-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}